<DOC>
	<DOCNO>NCT02957123</DOCNO>
	<brief_summary>The investigator design innovative proof-of-concept trial design provide data whether treatment/rehabilitation efficacy functional outcome patient organic brain syndrome improve intranasal inhalation bioactive factor ( BF ) , produce autologous M2 macrophage ( auto-M2-BFs ) . The rationale approach ability central nervous system repair important role macrophage regulation process . It find type 2 macrophage anti-inflammatory reparative potential , whereas M1 cell possess pro-inflammatory neurotoxic effect . Action M2 macrophages largely realize production wide variety bioactive factor ( cytokine , chemokines , growth factor , neuropeptides , microvesicles etc ) inhibit inflammation , protect neuron apoptosis , stimulate neurogenesis , growth remyelination axon , formation new synapsis activate angiogenesis . This study use auto-M2-BFs , therapeutic agent intranasal administration focus nose brain transport , mode delivery . Expected clinical effect treat subject : improvement cognitive function ( memory , language , attention ) ; correction focal neurological deficit ( paresis , spasticity , sensory disorder ) ; reduction vestibular/ataxic disorder ( vertigo , unsteadiness walking ) ; reduction headache ; reduction asthenia ( weakness , fatigue ) ; correction emotional disorder ( anxiety , depression ) .</brief_summary>
	<brief_title>Intranasal Inhalations Bioactive Factors Produced M2 Macrophages Patients With Organic Brain Syndrome</brief_title>
	<detailed_description>Following injury central nervous system ( CNS ) , immune-mediated inflammation profoundly affect ability neural cell survive regenerate . The role inflammation comprise mostly macrophage , controversial , since macrophage induce neuronal glial toxicity promote tissue repair . The opposite effect macrophage may condition functional heterogeneity . Thus , classical pro-inflammatory macrophage ( M1 ) tissue-destructive , anti-inflammatory ( M2 ) macrophages mediate tissue repair . In addition , M2 macrophages predominantly induce Th2 response , particularly beneficial CNS repair . Using low serum condition investigator generate M2-like macrophage evaluate phenotypic functional feature [ 1 , 2 ] . Our data indicate M2 macrophage , contrast pro-inflammatory M1 cell , produce significantly low level pro-inflammatory cytokine ( IL-1β , tumor necrosis factor-α , IL-6 , IL-18 , IL-12 ) , chemokines ( IL-8 , monocyte chemoattractant protein 1-1 ) Th1/Th2-cytokines ( interferon-γ , IL-2 , IL-4 ) couple high IL-10 level . M2 macrophages capable produce neurotrophic- ( brain-derived neurotrophic factor , insulin-like growth factor-1 ) , angiogenic- ( vascular endothelial growth factor ) , growth factor ( erythropoietin , granulocyte-colony stimulating factor , basic fibroblast growth factor , epidermal growth factor ) neuroprotective regenerative activity . Our pilot clinical trial demonstrate safety clinical efficacy intrathecal administration M2 macrophages child severe cerebral palsy [ 3 ] non-acute stroke patient [ 4 ] . Since cell-free culture medium M2 macrophages contains wide variety neurotrophic , immunoregulatory pro-angiogenic factor , investigator expect intranasal administration auto-M2-BFs improve treatment/rehabilitation efficacy functional outcome patient organic brain syndrome . Of note , intranasal administration M2-macrophage soluble factor allow delivery bioactive agent brain olfactory trigeminal way across brain-blood barrier .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Neurocognitive Disorders</mesh_term>
	<mesh_term>Brain Injury , Chronic</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<criteria>Adults : age 18 80 Persistent neurological deficit ( cognitive , mental , motor , vestibular/ataxic disorder result trauma , cardiovascular , neurodegenerative others cerebral injury ) , confirm clinically CT MRI A write informed consent patient close relative Psychiatric disorder Seizures Severe dementia Hepatic renal dysfunction Hemodynamic respiratory instability HIV uncontrolled bacterial , fungal , viral infection Pregnancy Malignancy Intolerance gentamicin / multiple drug allergy Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>macrophage M2 type</keyword>
	<keyword>cytokine</keyword>
	<keyword>intranasal administration</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>neuroregeneration</keyword>
	<keyword>organic brain syndrome</keyword>
	<keyword>neurocognitive disorder</keyword>
</DOC>